Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook
Connect to Fight Neglect: DNDi has launched a special website for its 10-year anniversary, dedicated to the voices of all actors in neglected disease R&D. We hope that YOU will connect to share your story as well!

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made in the short-term with six new treatments made available to forgotten patients since the creation of DNDi, in 2003.

However, major breakthroughs are still needed to treat patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.

SPOTLIGHT
«
»

AN ALTERNATIVE R&D MODEL

To mark its 10 year anniversary, DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. More

CHAGAS DISEASE

The soccer star Lionel Messi, having seen the Ricardo Preve documentary 'Chagas, A Silent Killer', speaks out about Chagas disease and calls for teamwork to treat patients and find altogether new treatments. More

SLEEPING SICKNESS

Fexinidazole: launch of Phase II/III clinical trial in the Democratic Republic of Congo and Central African Republic.The study, initiated by DNDi and its partners, will test the efficacy and safety of fexinidazole, with once daily tablets for ten days. More

PAEDIATRIC HIV

Testimonies of South African mothers: demonstrating the difficulties in administering current treatments for paediatric HIV More

LEISHMANIASIS

Voices for neglected diseases. Lemarus Tebakwani Lukeno has been treated with SSG&PM for kala-azar; read his and other patient stories More

MALARIA

280 million treatments of ASAQ, DNDi’s antimalarial combination therapy of Artesunate and Amodiaquine, have been distributed in over 30 countries since its launch in 2007! More

DNDi NEWS

   

April 13-15, 2014
FINDECHAGAS
4th Meeting of the International Association of People Affected by Chagas Disease
Santa Cruz, Bolivia
This is an event organized by and for associations. People affected by Chagas disease from more than ten countries will be represented.

April 13-16, 2014
5th FIP Pharmaceutical Sciences World Congress
Pharmaceutical sciences beyond 2020
Melbourne, Australia
DNDi is participating in a session on drug development efforts to combat tropical diseases.

April 17, 2014
Integrating Malaria into Sustainable Development Goals
Geneva Health Forum 2014
Geneva, Switzerland
The Swiss Malaria Group is hosting a Malaria Fishbowl to encourage dialogue on how the global malaria community can integrate with non-health sectors to help eliminate malaria. 

April 25 - May 13, 2014
Swiss Malaria Group Photo Exhibition
Engagement Schweiz: Gemeinsam Gegen Malaria
Berne, Switzerland
The Swiss Malaria Group is presenting a photo exhibition. Opening and apéro on World Malaria Day, April 25! 

See all events

DNDI WORLDWIDE

REPORT: 10 YEARS OF DNDi

DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more

TWITTER



Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License